BMRN stock on watch as FDA seeks additional data on hemophilia A drug (NASDAQ:BMRN)
seekingalpha.com
finance
2022-05-31 13:29:13

Sundry Photography/iStock Editorial via Getty Images Commercial-stage biotech BioMarin Pharmaceutical (NASDAQ:BMRN) announced on Tuesday that the FDA requested additional data for its planned Biologics Licensing Application (BLA) for hemophilia A therapy valoctocogene roxaparvovec. An investigational gene therapy, valoctocogene roxaparvovec, is currently undergoing European review for the treatment of severe hemophilia A. Last month, BioMarin (BMRN) announced plans to resubmit its BLA to the FDA in June 2022.
